Mechanisms for the transition from physiological to pathological cardiac hypertrophy
Open accessThe DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Abstract
The heart is capable of responding to stressful situations by increasing muscle mass, which is broadly defined as cardiac hypertrophy. This phenomenon minimizes ventricular wall stress for the heart undergoing a greater than normal workload. At initial stages, cardiac hypertrophy is associated with normal or enhanced cardiac function and is considered to be adaptive or physiological; however, at later stages, if the stimulus is not removed, it is associated with contractile dysfunction and is termed as pathological cardiac hypertrophy. It is during physiological cardiac hypertrophy where the function of subcellular organelles, including the sarcolemma, sarcoplasmic reticulum, mitochondria, and myofibrils, may be upregulated, while pathological cardiac hypertrophy is associated with downregulation of these subcellular activities. The transition of physiological cardiac hypertrophy to pathological cardiac hypertrophy may be due to the reduction in blood supply to hypertrophied myocardium as a consequence of reduced capillary density. Oxidative stress, inflammatory processes, Ca 2+-handling abnormalities, and apoptosis in cardiomyocytes are suggested to play a critical role in the depression of contractile function during the development of pathological hypertrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,725
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853 · cited 3×
“Development of Apoptosis Apoptosis is a distinct form of cell death, involving the genetically determined elimination of cells (Elmore 2007).”
BackgroundInfluentialRisau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727 · cited 2×
“Reduction of Capillary Density Angiogenesis is a fundamental process by which new blood vessels are formed (Dvorak et al. 1995; Folkman and Shing 1992; Hudlicka et al. 1992; Risau 1997).”
BackgroundInfluentialMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491 · cited 1×
“Various classes of cytokines include: interleukins, chemokines, interferons, lymphokines, the tumor necrosis factor (TNF) family, and the transforming growth factor- (TGF-) family (Parkin and Cohen 2001; Platanias 2005; Sun and Fink 2007).”
BackgroundEvidence for Cardiomyocyte Renewal in Humans
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabé-Heider, F., Walsh, S., Zupicich, J., Alkass, K., Buchholz, B. A., Druid, H., et al. (2009) · Science · doi:10.1126/science.1164680 · Cited by 3,130
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Nordberg, J., & Arnér, E. S. J. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00724-9 · Cited by 2,662 · cited 2×
“NO has been described as a member of the free radical family; however, NO is also a free radical scavenger, reacting with other ROS to generate less reactive molecules (Nordberg and Arnér 2001).”
BackgroundFolkman, J., & Shing, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49853-0 · Cited by 2,654
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582 · cited 1×
“In patients with heart failure, TNF- levels have been reported to be elevated (Fang et al. 2017; Levine et al. 1990) and TNF- gene expression is positively correlated with level, severity, and etiology of disease in this population (Eskandari et al. 2018).”
BackgroundA Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Wall stress and patterns of hypertrophy in the human left ventricle.
Grossman, W., Jones, D., & McLaurin, L. P. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108079 · Cited by 2,403 · cited 1×
“Cardiac hypertrophy minimizes ventricular wall stress and maintains contractile function when the heart experiences a greater than normal workload (Grossman et al. 1975).”
BackgroundHayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826 · cited 1×
“Cytosolic or intracellular Ca2+-overload and exhausted Ca2+ stores disturb protein folding, leading to an unfolded protein response and endoplasmic reticulum (ER) stress (Hayashi and Su 2007).”
BackgroundApoptosis in the Failing Human Heart
Olivetti, G., Abbi, R., Quaini, F., Kajstura, J., Cheng, W., Nitahara, J. A., Quaini, E., Di Loreto, C., Beltrami, C. A., Krajewski, S., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704173361603 · Cited by 1,673 · cited 1×
“…has been Page 18 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Draft 19 implicated in many forms of CVD, such as myocardial ischemia/reperfusion (I/R) injury and heart failure (Gottlieb et al. 1994; Narula et al. 1996; Olivetti et al. 1997).”
BackgroundEvans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.1 · Cited by 1,482 · cited 1×
“In addition to inflicting direct molecular damage, ROS activate different signal transduction pathways involved in the induction of cellular injury (Evans et al. 2003).”
BackgroundAn overview of the immune system
Parkin, J., & Cohen, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04904-7 · Cited by 1,460 · cited 2×
“Various classes of cytokines include: interleukins, chemokines, interferons, lymphokines, the tumor necrosis factor (TNF) family, and the transforming growth factor- (TGF-) family (Parkin and Cohen 2001; Platanias 2005; Sun and Fink 2007).”
BackgroundReperfusion injury induces apoptosis in rabbit cardiomyocytes.
Gottlieb, R. A., Burleson, K. O., Kloner, R. A., Babior, B. M., & Engler, R. L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117504 · Cited by 1,441
Apoptosis in Myocytes in End-Stage Heart Failure
Narula, J., Haider, N., Virmani, R., DiSalvo, T. G., Kolodgie, F. D., Hajjar, R. J., Schmidt, U., Semigran, M. J., Dec, G. W., & Khaw, B.-A. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610173351603 · Cited by 1,430 · cited 1×
“…has been Page 18 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Draft 19 implicated in many forms of CVD, such as myocardial ischemia/reperfusion (I/R) injury and heart failure (Gottlieb et al. 1994; Narula et al. 1996; Olivetti et al. 1997).”
BackgroundFibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428 · cited 2×
“Page 5 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Draft 6 Excessive extracellular matrix contributes to reduced systolic and diastolic function, and it impairs electrical conduction, predisposing the heart to arrythmias (Rockey et al. 2015).”
BackgroundCardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities
Braunwald, E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711063371906 · Cited by 1,424 · cited 1×
“…to tissue injury, the heart activates the innate immune system to begin tissue repair mechanisms (Schumacher and Naga Prasad 2018) which are associated with the occurrence of significant increases in the levels of different pro-inflammatory cytokines (Braunwald 1997; Valen 2011; Mann 2015).”
BackgroundInflammation as a Cardiovascular Risk Factor
Willerson, J. T., & Ridker, P. M. (2004) · Circulation · doi:10.1161/01.cir.0000129535.04194.38 · Cited by 1,304 · cited 2×
“However, given the diverse and unique nature of cardiac stress, the pro-inflammatory response is extended in the heart (Willerson and Ridker 2004) and if unattended by anti-inflammatory mechanisms, this prolonged inflammatory response transitions to chronic inflammation (Mann 2003); a key…”
BackgroundOld, new and emerging functions of caspases
Shalini, S., Dorstyn, L., Dawar, S., & Kumar, S. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.216 · Cited by 1,267
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily
Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., Zhang, H. P., Donnellan, M., Mahler, S., Pryor, K., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11514 · Cited by 1,177
Hein, S., Arnon, E., Kostin, S., Schönburg, M., Elsässer, A., Polyakova, V., Bauer, E. P., Klövekorn, W.-P., & Schaper, J. (2003) · Circulation · doi:10.1161/01.cir.0000051865.66123.b7 · Cited by 1,102
Hill, J. A., & Olson, E. N. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072139 · Cited by 1,065
Transforming growth factor (TGF)-β signaling in cardiac remodeling
Dobaczewski, M., Chen, W., & Frangogiannis, N. G. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.033 · Cited by 934 · cited 1×
“…cardiac remodeling, cardiac fibrosis, and pathological cardiac hypertrophy (Li et al. 1997; Lijnen et al. 2000; Fielitz et al. 2001; Hein Page 16 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Draft 17 et al. 2003; Dobaczewski et al. 2011).”
BackgroundAbnormal intracellular calcium handling in myocardium from patients with end-stage heart failure.
Gwathmey, J. K., Copelas, L., MacKinnon, R., Schoen, F. J., Feldman, M. D., Grossman, W., & Morgan, J. P. (1987) · Circulation Research · doi:10.1161/01.res.61.1.70 · Cited by 924
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y., Harada, M., et al. (2007) · Nature · doi:10.1038/nature05602 · Cited by 905
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894 · cited 2×
“…function in physiological and pathological cardiac hypertrophy have appeared in the literature (Wikman-Coffelt et al. 1979; Dhalla et al. 1987; Bernardo et al. 2010; Maillet et al. 2013; Tham et al. 2015); however, only some scattered information regarding the mechanisms of changes in cardiac…”
BackgroundPhysiological and pathological cardiac hypertrophy
Shimizu, I., & Minamino, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.001 · Cited by 887 · cited 5×
“…hypertrophy is classified as physiological hypertrophy when it is associated with normal or enhanced cardiac function and is generally seen to occur in response to growth of the body, pregnancy, or exercise (Hill and Olson 2008; Shimizu and Minamino 2016; Weeks and McMullen 2011).”
BackgroundInfluentialRole of Oxidative Stress in Cardiac Hypertrophy and Remodeling
Takimoto, E., & Kass, D. A. (2007) · Hypertension · doi:10.1161/01.hyp.0000254415.31362.a7 · Cited by 770 · cited 3×
“ROS include a variety of chemical molecules, such as superoxide (O2-), hydrogen peroxide, and hydroxyl radical (OH) (Takimoto and Kass 2007).”
BackgroundTumor necrosis factor in the heart
Meldrum, D. R. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.3.r577 · Cited by 746
Rose, B. A., Force, T., & Wang, Y. (2010) · Physiological Reviews · doi:10.1152/physrev.00054.2009 · Cited by 723 · cited 1×
“TGF- activates p38 MAPK, further contributing to pathological cardiac remodeling (Rose et al. 2010).”
BackgroundTham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., & McMullen, J. R. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1477-x · Cited by 708 · cited 9×
“Several cytokines have been reported to be involved in the pathogenesis of various forms of CVD (Feldman et al. 2000; Valen 2001; Khan and Sheppard 2006).”
BackgroundInfluentialCytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693 · cited 1×
“…both beneficial and deleterious effects on cellular function and are involved in the immune response, inflammation, sepsis, reproduction, trauma, cancer, and CVD (Padua et al. 1995; Parkin and Cohen 2001; Saini et al. 2005; Lee and Margolin 2011; Sivarajasingam et al. 2016; Guisasola et al. 2018).”
BackgroundInnate Immunity and the Failing Heart: The Cytokine Hypothesis Revisited
Mann, D. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.302317 · Cited by 689 · cited 1×
“…to tissue injury, the heart activates the innate immune system to begin tissue repair mechanisms (Schumacher and Naga Prasad 2018) which are associated with the occurrence of significant increases in the levels of different pro-inflammatory cytokines (Braunwald 1997; Valen 2011; Mann 2015).”
BackgroundMoulton, K. S., Heller, E., Konerding, M. A., Flynn, E., Palinski, W., & Folkman, J. (1999) · Circulation · doi:10.1161/01.cir.99.13.1726 · Cited by 688 · cited 1×
“…factor, and angiogenin) and anti-angiogenic (endostatin and vascular endothelial growth inhibitor) have been identified, and their roles in the process of angiogenesis have been evaluated in different disease states (Jackson et al. 1997; Li et al. 1996; Moulton et al. 1999; Zhai et al. 1999).”
BackgroundThe immune system and cardiac repair
FRANGOGIANNIS, N. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.06.007 · Cited by 641 · cited 8×
“Several cytokines have been reported to be involved in the pathogenesis of various forms of CVD (Feldman et al. 2000; Valen 2001; Khan and Sheppard 2006).”
BackgroundInfluentialCellular Responses to DNA Damage
Norbury, C. J., & Hickson, I. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.367 · Cited by 623 · cited 1×
“Apoptosis also occurs as an immune response, such as during immune reactions or when cells are damaged by disease (Norbury and Hickson 2001).”
BackgroundAngiogenesis in skeletal and cardiac muscle
Hudlicka, O., Brown, M., & Egginton, S. (1992) · Physiological Reviews · doi:10.1152/physrev.1992.72.2.369 · Cited by 612 · cited 3×
“Reduction of Capillary Density Angiogenesis is a fundamental process by which new blood vessels are formed (Dvorak et al. 1995; Folkman and Shing 1992; Hudlicka et al. 1992; Risau 1997).”
BackgroundStructural basis of end-stage failure in ischemic cardiomyopathy in humans.
Beltrami, C. A., Finato, N., Rocco, M., Feruglio, G. A., Puricelli, C., Cigola, E., Quaini, F., Sonnenblick, E. H., Olivetti, G., & Anversa, P. (1994) · Circulation · doi:10.1161/01.cir.89.1.151 · Cited by 595 · cited 1×
“…cardiac hypertrophy is accompanied by a significant increase in the number of myocardial capillaries, whereas myocardial capillary density is reduced in the pathologically hypertrophied heart (Beltrami et al. 1994; Hudlicka et al. 1992; Jo et al. 2001; Weeks et al. 2012; White et al. 1998).”
BackgroundZhang, T., Maier, L. S., Dalton, N. D., Miyamoto, S., Ross, J., Bers, D. M., & Brown, J. H. (2003) · Circulation Research · doi:10.1161/01.res.0000069686.31472.c5 · Cited by 556 · cited 2×
“…Journal of Physiology and Pharmacology Draft 10 kinase, p38 mitogen-activated protein kinase (MAPK), and nuclear factor -light-chain-enhancer of activated B cells (Gray et al. 1998; Takimoto and Kass 2007; van Wamel et al. 2001; Weber et al. 2005; W. Zhang et al. 2003a).”
BackgroundMolecular basis of physiological heart growth: fundamental concepts and new players
Maillet, M., van Berlo, J. H., & Molkentin, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3495 · Cited by 536
Jo, S.-H., Son, M.-K., Koh, H.-J., Lee, S.-M., Song, I.-H., Kim, Y.-O., Lee, Y.-S., Jeong, K.-S., Kim, W. B., Park, J.-W., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010120200 · Cited by 536 · cited 3×
“…cardiac hypertrophy is accompanied by a significant increase in the number of myocardial capillaries, whereas myocardial capillary density is reduced in the pathologically hypertrophied heart (Beltrami et al. 1994; Hudlicka et al. 1992; Jo et al. 2001; Weeks et al. 2012; White et al. 1998).”
BackgroundNakamura, K., Fushimi, K., Kouchi, H., Mihara, K., Miyazaki, M., Ohe, T., & Namba, M. (1998) · Circulation · doi:10.1161/01.cir.98.8.794 · Cited by 510 · cited 1×
“Antioxidant treatment, using butylated hydroxy anisole and vitamin E, inhibited Angiotensin II (Ang II) and tumor necrosis factor- (TNF-)-induced pathological cardiac hypertrophy (Nakamura et al. 1998).”
MethodThe role of tumor necrosis factor in the pathophysiology of heart failure
Feldman, A. M., Combes, A., Wagner, D., Kadakomi, T., Kubota, T., You Li, Y., & McTiernan, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00600-2 · Cited by 506 · cited 8×
“Several cytokines have been reported to be involved in the pathogenesis of various forms of CVD (Feldman et al. 2000; Valen 2001; Khan and Sheppard 2006).”
BackgroundInfluentialKhan, R., & Sheppard, R. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02336.x · Cited by 501 · cited 1×
“Several cytokines have been reported to be involved in the pathogenesis of various forms of CVD (Feldman et al. 2000; Valen 2001; Khan and Sheppard 2006).”
BackgroundFeldman, M. D., Copelas, L., Gwathmey, J. K., Phillips, P., Warren, S. E., Schoen, F. J., Grossman, W., & Morgan, J. P. (1987) · Circulation · doi:10.1161/01.cir.75.2.331 · Cited by 486 · cited 2×
“…of Physiology and Pharmacology Draft 13 Previous research has reported that Ca2+-handling abnormalities occur in the failing heart and contribute to the development of contractile dysfunction (Feldman et al. 1987; Gwathmey et al. 1987; Lindner et al. 2002; Yeh et al. 2008; Respress et al. 2014).”
BackgroundArai, M., Alpert, N. R., MacLennan, D. H., Barton, P., & Periasamy, M. (1993) · Circulation Research · doi:10.1161/01.res.72.2.463 · Cited by 479 · cited 1×
“Reduced SERCA2a gene expression has also been observed in experimental models of heart failure (Kawase et al. 2008; Kiss et al. 1995; O’Rourke et al. 1999), as well as in the failing human heart (Arai et al. 1993; Hasenfuss 1998).”
BackgroundInduction of Cardiac Fibrosis by Transforming Growth Factor-β1
Lijnen, P. J., Petrov, V. V., & Fagard, R. H. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.3032 · Cited by 464 · cited 1×
“TGF- is involved in the progression of pathological cardiac remodeling, cardiac fibrosis, and pathological cardiac hypertrophy (Li et al. 1997; Lijnen et al. 2000; Fielitz et al. 2001; Hein Page 16 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and…”
BackgroundPrevention of Cardiac Hypertrophy in Mice by Calcineurin Inhibition
Sussman, M. A., Lim, H. W., Gude, N., Taigen, T., Olson, E. N., Robbins, J., Colbert, M. C., Gualberto, A., Wieczorek, D. F., & Molkentin, J. D. (1998) · Science · doi:10.1126/science.281.5383.1690 · Cited by 461
Nuclear factor kappa-B and the heart
Valen, G., Yan, Z.-Q., & Hansson, G. K. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01377-8 · Cited by 447
Meléndez, G. C., McLarty, J. L., Levick, S. P., Du, Y., Janicki, J. S., & Brower, G. L. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.148635 · Cited by 442
Haq, S., Choukroun, G., Lim, H., Tymitz, K. M., del Monte, F., Gwathmey, J., Grazette, L., Michael, A., Hajjar, R., Force, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.5.670 · Cited by 440 · cited 1×
“Calcineurin activity is elevated in the cardiomyocytes of patients with pathological cardiac hypertrophy (Haq et al. 2001).”
BackgroundAlterations of calcium-regulatory proteins in heart failure
Hasenfuss, G. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00277-0 · Cited by 432 · cited 2×
“Reduced SERCA2a gene expression has also been observed in experimental models of heart failure (Kawase et al. 2008; Kiss et al. 1995; O’Rourke et al. 1999), as well as in the failing human heart (Arai et al. 1993; Hasenfuss 1998).”
BackgroundGray, M. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00121-7 · Cited by 417 · cited 1×
“…Journal of Physiology and Pharmacology Draft 10 kinase, p38 mitogen-activated protein kinase (MAPK), and nuclear factor -light-chain-enhancer of activated B cells (Gray et al. 1998; Takimoto and Kass 2007; van Wamel et al. 2001; Weber et al. 2005; W. Zhang et al. 2003a).”
BackgroundApoptosis in pressure overload-induced heart hypertrophy in the rat.
Teiger, E., Than, V. D., Richard, L., Wisnewsky, C., Tea, B. S., Gaboury, L., Tremblay, J., Schwartz, K., & Hamet, P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118747 · Cited by 408 · cited 2×
“In this experiment, the rate of cardiomyocyte apoptosis reached its maximum after four days of pressure-overload, while cardiac hypertrophy continued to develop for thirty days (Teiger et al. 1996).”
BackgroundMünzel, T., Gori, T., Keaney, J. F., Maack, C., & Daiber, A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv305 · Cited by 394 · cited 16×
“Along with defense against ROS, NO is implicated in cardiomyocyte growth.”
BackgroundInfluentialSun, M., Chen, M., Dawood, F., Zurawska, U., Li, J. Y., Parker, T., Kassiri, Z., Kirshenbaum, L. A., Arnold, M., Khokha, R., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.643585 · Cited by 383 · cited 1×
“TNF- is also implicated in pathological cardiac remodeling, cardiac fibrosis, and pathological cardiac hypertrophy (Mei Sun et al. 2007).”
BackgroundBoluyt, M. O., O'Neill, L., Meredith, A. L., Bing, O. H., Brooks, W. W., Conrad, C. H., Crow, M. T., & Lakatta, E. G. (1994) · Circulation Research · doi:10.1161/01.res.75.1.23 · Cited by 346
Kawase, Y., Ly, H. Q., Prunier, F., Lebeche, D., Shi, Y., Jin, H., Hadri, L., Yoneyama, R., Hoshino, K., Takewa, Y., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.014 · Cited by 344 · cited 1×
“Reduced SERCA2a gene expression has also been observed in experimental models of heart failure (Kawase et al. 2008; Kiss et al. 1995; O’Rourke et al. 1999), as well as in the failing human heart (Arai et al. 1993; Hasenfuss 1998).”
BackgroundO’Rourke, B., Kass, D. A., Tomaselli, G. F., Kääb, S., Tunin, R., & Marbán, E. (1999) · Circulation Research · doi:10.1161/01.res.84.5.562 · Cited by 341 · cited 1×
“Reduced SERCA2a gene expression has also been observed in experimental models of heart failure (Kawase et al. 2008; Kiss et al. 1995; O’Rourke et al. 1999), as well as in the failing human heart (Arai et al. 1993; Hasenfuss 1998).”
BackgroundVEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis
Li, J., Brown, L. F., Hibberd, M. G., Grossman, J. D., Morgan, J. P., & Simons, M. (1996) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1996.270.5.h1803 · Cited by 340 · cited 1×
“…factor, and angiogenin) and anti-angiogenic (endostatin and vascular endothelial growth inhibitor) have been identified, and their roles in the process of angiogenesis have been evaluated in different disease states (Jackson et al. 1997; Li et al. 1996; Moulton et al. 1999; Zhai et al. 1999).”
Backgroundde la Bastie, D., Levitsky, D., Rappaport, L., Mercadier, J. J., Marotte, F., Wisnewsky, C., Brovkovich, V, Schwartz, K., & Lompré, A. M. (1990) · Circulation Research · doi:10.1161/01.res.66.2.554 · Cited by 339 · cited 2×
“Both upregulation and downregulation of SR gene expression for SR proteins and Ca2+-transport activities have been observed without significant changes in myofibrillar ATPase activities (Arai 1996; Heyliger et al. 1985; de la Bastie et al. 1990; Kiss et al. 1995; Dhalla et al. 1987).”
BackgroundMolecules in focus Transforming growth factor-beta (TGF-β)
Clark, D. A., & Coker, R. (1998) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(97)00128-3 · Cited by 337 · cited 1×
“The TGF- family of cytokines control a range of cellular processes (Clark and Coker 1998).”
BackgroundKoitabashi, N., Danner, T., Zaiman, A. L., Pinto, Y. M., Rowell, J., Mankowski, J., Zhang, D., Nakamura, T., Takimoto, E., & Kass, D. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44824 · Cited by 334
Izumiya, Y., Shiojima, I., Sato, K., Sawyer, D. B., Colucci, W. S., & Walsh, K. (2006) · Hypertension · doi:10.1161/01.hyp.0000215207.54689.31 · Cited by 326 · cited 1×
“Cardiac hypertrophy must be matched with increased density of myocardial capillaries to ensure adaptation to greater cardiac demand and to preserve cardiac function (Izumiya et al. 2006).”
BackgroundStress-Activated Cytokines and The Heart: From Adaptation to Maladaptation
Mann, D. L. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142249 · Cited by 297 · cited 2×
“…and Ridker 2004) and if unattended by anti-inflammatory mechanisms, this prolonged inflammatory response transitions to chronic inflammation (Mann 2003); a key characteristic of such chronic cardiac inflammation is increased generation of proinflammatory cytokines within the heart (Mann 2003).”
BackgroundRole of cytokines and inflammation in heart function during health and disease
Bartekova, M., Radosinska, J., Jelemensky, M., & Dhalla, N. S. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9716-x · Cited by 293 · cited 1×
“…of pathological cardiac hypertrophy as a result of intracellular Ca2+-overload are shown in Figure 2B. d. Generation of Pro-Inflammatory Cytokines Cytokines are small proteins which serve as signaling mechanisms for the regulation of cellular function in health and disease (Bartekova et al. 2018).”
BackgroundSelf-citationYeh, Y.-H., Wakili, R., Qi, X.-Y., Chartier, D., Boknik, P., Kääb, S., Ravens, U., Coutu, P., Dobrev, D., & Nattel, S. (2008) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.107.754788 · Cited by 279 · cited 2×
“…of Physiology and Pharmacology Draft 13 Previous research has reported that Ca2+-handling abnormalities occur in the failing heart and contribute to the development of contractile dysfunction (Feldman et al. 1987; Gwathmey et al. 1987; Lindner et al. 2002; Yeh et al. 2008; Respress et al. 2014).”
BackgroundSun, M., Dawood, F., Wen, W.-H., Chen, M., Dixon, I., Kirshenbaum, L. A., & Liu, P. P. (2004) · Circulation · doi:10.1161/01.cir.0000147233.10318.23 · Cited by 275
Wikman-Coffelt, J., Parmley, W. W., & Mason, D. T. (1979) · Circulation Research · doi:10.1161/01.res.45.6.697 · Cited by 274 · cited 2×
“…several reviews concerning the status of cardiac function in physiological and pathological cardiac hypertrophy have appeared in the literature (Wikman-Coffelt et al. 1979; Dhalla et al. 1987; Bernardo et al. 2010; Maillet et al. 2013; Tham et al. 2015); however, only some scattered…”
BackgroundFeil, R., Lohmann, S. M., de Jonge, H., Walter, U., & Hofmann, F. (2003) · Circulation Research · doi:10.1161/01.res.0000100390.68771.cc · Cited by 271 · cited 1×
“NO elevates cGMP levels within cardiomyocytes, modulating cardiomyocyte function, growth, and remodeling (Feil et al. 2003).”
BackgroundShiomi, T., Tsutsui, H., Matsusaka, H., Murakami, K., Hayashidani, S., Ikeuchi, M., Wen, J., Kubota, T., Utsumi, H., & Takeshita, A. (2004) · Circulation · doi:10.1161/01.cir.0000109701.77059.e9 · Cited by 260
NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy
Nakagami, H. (2003) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(03)00145-7 · Cited by 255 · cited 1×
“As well, the antioxidants, probucol, tempol, and Nacetylcysteine, blunted Ang II-induced pathological cardiac hypertrophy through the inhibition of O2- production within cardiomyocytes (Nakagami et al. 2003).”
BackgroundLuo, Y.-X., Tang, X., An, X.-Z., Xie, X.-M., Chen, X.-F., Zhao, X., Hao, D.-L., Chen, H.-Z., & Liu, D.-P. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw138 · Cited by 241 · cited 4×
“In this model, SIRT4 deficient mice, when compared to WT mice, generated fewer ROS and possessed greater Page 10 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Draft 11 levels of antioxidant enzyme activity (Luo et al. 2017).”
BackgroundMethodResultInfluentialYue, Y., Meng, K., Pu, Y., & Zhang, X. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.08.018 · Cited by 240 · cited 2×
“TGF- was also reported to be involved in the induction of diabetic cardiomyopathy, a condition characterized by cardiac remodeling (Yue et al. 2017).”
BackgroundOxidative Stress Causes Heart Failure with Impaired Mitochondrial Respiration
Nojiri, H., Shimizu, T., Funakoshi, M., Yamaguchi, O., Zhou, H., Kawakami, S., Ohta, Y., Sami, M., Tachibana, T., Ishikawa, H., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602118200 · Cited by 230
Jackson, J. R., Minton, J. A. L., Ho, M. L., Wei, N., & Winkler, J. (1997) · PubMed · Cited by 227
Li, R.-K., Li, G., Mickle, D. A. G., Weisel, R. D., Merante, F., Luss, H., Rao, V., Christakis, G. T., & Williams, W. G. (1997) · Circulation · doi:10.1161/01.cir.96.3.874 · Cited by 211 · cited 1×
“TGF- is involved in the progression of pathological cardiac remodeling, cardiac fibrosis, and pathological cardiac hypertrophy (Li et al. 1997; Lijnen et al. 2000; Fielitz et al. 2001; Hein Page 16 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and…”
BackgroundProinflammatory cytokines in heart failure: double-edged swords
Hedayat, M., Mahmoudi, M. J., Rose, N. R., & Rezaei, N. (2010) · Heart Failure Reviews · doi:10.1007/s10741-010-9168-4 · Cited by 205 · cited 1×
“TNF- has a range of effects on heart function and pathological effects in CVD (Frangogiannis 2008; Hedayat et al. 2010).”
BackgroundZhang, T., Kohlhaas, M., Backs, J., Mishra, S., Phillips, W., Dybkova, N., Chang, S., Ling, H., Bers, D. M., Maier, L. S., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707083200 · Cited by 201
Hamasaki, S., Al Suwaidi, J., Higano, S. T., Miyauchi, K., Holmes, D. R., & Lerman, A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00594-5 · Cited by 198 · cited 1×
“…et al. 2000; Yunlong 2007); however, there is ample evidence to indicate that capillary density within the heart is decreased at the later stages of pathological cardiac hypertrophy (Flanagan et al. 1991; Hamasaki et al. 2000; Hudlicka et al. 1992; Karch et al. 2005; Shimamatsu and Toshima 1987).”
BackgroundKiss, E., Ball, N. A., Kranias, E. G., & Walsh, R. A. (1995) · Circulation Research · doi:10.1161/01.res.77.4.759 · Cited by 195 · cited 2×
“Reduced SERCA2a gene expression has also been observed in experimental models of heart failure (Kawase et al. 2008; Kiss et al. 1995; O’Rourke et al. 1999), as well as in the failing human heart (Arai et al. 1993; Hasenfuss 1998).”
BackgroundOxidative stress and stress signaling: menace of diabetic cardiomyopathy
WOLD, L. E., CEYLAN-ISIK, A. F., & REN, J. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00146.x · Cited by 192 · cited 2×
“plays a significant role in the development of various pathologies due to the action of ROS to oxidize DNA, proteins, and lipid membranes directly (Wold et al. 2005).”
BackgroundGwathmey, J. K., Warren, S. E., Briggs, G. M., Copelas, L., Feldman, M. D., Phillips, P. J., Callahan, M., Schoen, F. J., Grossman, W., & Morgan, J. P. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115061 · Cited by 183 · cited 1×
“On the other hand, in cardiomyocytes of humans manifesting pathological cardiac hypertrophy, Ca2+ transients are prolonged (Gwathmey et al. 1991).”
Backgroundde Boer, R. A., Pinto, Y. M., & van Veldhuisen, D. J. (2003) · Microcirculation · doi:10.1038/sj.mn.7800188 · Cited by 180
Tumor Necrosis Factor-α in Heart Failure: an Updated Review
Schumacher, S. M., & Naga Prasad, S. V. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1067-7 · Cited by 178 · cited 1×
“In response to tissue injury, the heart activates the innate immune system to begin tissue repair mechanisms (Schumacher and Naga Prasad 2018) which are associated with the occurrence of significant increases in the levels of different pro-inflammatory cytokines (Braunwald 1997; Valen 2011; Mann…”
BackgroundKreusser, M. M., Lehmann, L. H., Keranov, S., Hoting, M.-O., Oehl, U., Kohlhaas, M., Reil, J.-C., Neumann, K., Schneider, M. D., Hill, J. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.006185 · Cited by 177 · cited 2×
“The development of this favourable phenotype was attributed to the inhibition of CaMKII-induced pathological cardiac hypertrophy (Kreusser et al. 2014).”
BackgroundHuang, Q., Zhou, H. J., Zhang, H., Huang, Y., Hinojosa-Kirschenbaum, F., Fan, P., Yao, L., Belardinelli, L., Tellides, G., Giordano, F. J., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012725 · Cited by 173
The Athlete's Heart vs. the Failing Heart: Can Signaling Explain the Two Distinct Outcomes?
Weeks, K. L., & McMullen, J. R. (2011) · Physiology · doi:10.1152/physiol.00043.2010 · Cited by 171 · cited 3×
“Pathological cardiac hypertrophy generally occurs in the presence of cardiovascular disease (CVD) (Tham et al. 2015), and it can ultimately contribute to the development of heart failure (Weeks and McMullen 2011).”
BackgroundExercise training in swine promotes growth of arteriolar bed and capillary angiogenesis in heart
White, F. C., Bloor, C. M., McKirnan, M. D., & Carroll, S. M. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.3.1160 · Cited by 168 · cited 1×
“…cardiac hypertrophy is accompanied by a significant increase in the number of myocardial capillaries, whereas myocardial capillary density is reduced in the pathologically hypertrophied heart (Beltrami et al. 1994; Hudlicka et al. 1992; Jo et al. 2001; Weeks et al. 2012; White et al. 1998).”
BackgroundSteinhauser, M. L., & Lee, R. T. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100175 · Cited by 168 · cited 1×
“Although there is some evidence to suggest a small number of cardiomyocytes are able to re-enter the cell cycle, it is generally held that the majority of cardiomyocytes are post-mitotic, and are thus, unable to divide (Bergmann et al. 2009; Steinhauser and Lee 2011).”
BackgroundAPOPTOSIS IN THE CARDIOVASCULAR SYSTEM
Bennett, M. R. (2002) · Heart · doi:10.1136/heart.87.5.480 · Cited by 165 · cited 1×
“Cardiomyocytes have also been reported to undergo apoptosis in response to harmful stimuli, including oxidative stress, mechanical stretch, and rapid pace (Bennett 2002).”
BackgroundEffects of exercise training on cardiac function, gene expression, and apoptosis in rats
Jin, H., Yang, R., Li, W., Lu, H., Ryan, A. M., Ogasawara, A. K., Peborgh, J. V., & Paoni, N. F. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.6.h2994 · Cited by 162 · cited 1×
“Pathological cardiac hypertrophy is typically associated with cardiomyocyte apoptosis (Li et al. 2017), while cardiomyocyte apoptosis is not associated with physiological cardiac hypertrophy (Jin et al. 2000).”
BackgroundFielitz, J., Hein, S., Mitrovic, V., Pregla, R., Zurbrügg, H. R., Warnecke, C., Schaper, J., Fleck, E., & Regitz-Zagrosek, V. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01170-6 · Cited by 162 · cited 1×
“…in the progression of pathological cardiac remodeling, cardiac fibrosis, and pathological cardiac hypertrophy (Li et al. 1997; Lijnen et al. 2000; Fielitz et al. 2001; Hein Page 16 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Draft 17 et al.…”
BackgroundWeeks, K. L., Gao, X., Du, X., Boey, E. J. H., Matsumoto, A., Bernardo, B. C., Kiriazis, H., Cemerlang, N., Tan, J. W., Tham, Y. K., et al. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.966622 · Cited by 159 · cited 1×
“…cardiac hypertrophy is accompanied by a significant increase in the number of myocardial capillaries, whereas myocardial capillary density is reduced in the pathologically hypertrophied heart (Beltrami et al. 1994; Hudlicka et al. 1992; Jo et al. 2001; Weeks et al. 2012; White et al. 1998).”
BackgroundLi, M., Georgakopoulos, D., Lu, G., Hester, L., Kass, D. A., Hasday, J., & Wang, Y. (2005) · Circulation · doi:10.1161/01.cir.0000165117.71483.0c · Cited by 159 · cited 1×
“In TNF- KO mice, apoptosis and pathological cardiac remodeling were reported to be reduced following myocardial infarction (Mei Sun, 2004). p38 MAPK has been reported to induce release of TNF- and it is activated by cardiac pressure overload (Li et al. 2005).”
BackgroundInfluentialZHAI, Y., NI, J., JIANG, G., LU, J., XING, L., LINCOLN, C., CARTER, K. C., JANAT, F., KOZAK, D., XU, S., et al. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.181 · Cited by 158 · cited 1×
“Active CaM initiates signaling pathways involving Ca2+/CaM/CaMKII/myocyte enhancer factor2 (MEF-2) and Ca2+/CaM/CaMKII/calcineurin/nuclear factor of activated T-cells (NFAT), which are pro-hypertrophic signaling pathways (Zhang et al. 2007).”
BackgroundKomuro, I., Kurabayashi, M., Shibazaki, Y., Takaku, F., & Yazaki, Y. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113989 · Cited by 156 · cited 1×
“Along with impairments in SERCA2a activity, pathological cardiac hypertrophy is associated with reduced SERCA2a gene expression (de la Bastie et al. 1990; Komuro et al. 1989).”
BackgroundMorphometry of exercise-induced right ventricular hypertrophy in the rat.
Anversa, P., Levicky, V, Beghi, C., McDonald, S. L., & Kikkawa, Y. (1983) · Circulation Research · doi:10.1161/01.res.52.1.57 · Cited by 154 · cited 1×
“…Journal of Physiology and Pharmacology Draft 8 Morphometric analysis of physiologically hypertrophied hearts in animal models has revealed that coronary angiogenesis and cardiomyocyte hypertrophy occur proportionally (Anversa and Capasso 1991; Anversa et al. 1983).”
BackgroundCaMKII oxidative activation and the pathogenesis of cardiac disease
Luczak, E. D., & Anderson, M. E. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.02.004 · Cited by 152 · cited 1×
“CaMKII is a downstream signaling effector of the Gq signaling pathway (Luczak and Anderson 2014).”
BackgroundRole of mitogen-activated protein kinase in cardiac hypertrophy and heart failure.
Zhang, W., Elimban, V., NIJJAR, M. S., Gupta, S. K., & Dhalla, N. S. (2003) · PubMed · Cited by 151
Self-citationStructural Analysis of Chemokine Receptor–Ligand Interactions
Arimont, M., Sun, S., Leurs, R., Smit, M. J., de Esch, I. J. P., & de Graaf, C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01309 · Cited by 147 · cited 1×
“These transmembrane receptors are divided into six types according to their structure (Arimont et al. 2017; Grötzinger 2002) and include type I and type II cytokine receptors, the immunoglobin superfamily of receptors, the TNF receptor family, chemokine receptors, and TGF- receptors.”
BackgroundColes, B., Fielding, C. A., Rose‐John, S., Scheller, J., Jones, S. A., & O’Donnell, V. B. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061078 · Cited by 145 · cited 1×
“The interleukins, 1 (IL-1) and 6 (IL-6), are reported to be implicated in the pathogenesis of cardiac dysfunction and the development of pathological cardiac hypertrophy (Cannon 2000; Coles et al. 2007; Meier et al. 2009; Meléndez et al. 2010).”
BackgroundGogiraju, R., Xu, X., Bochenek, M. L., Steinbrecher, J. H., Lehnart, S. E., Wenzel, P., Kessel, M., Zeisberg, E. M., Dobbelstein, M., & Schäfer, K. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.001770 · Cited by 143
A New Class of Reverse Signaling Costimulators Belongs to the TNF Family
Sun, M., & Fink, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4307 · Cited by 142 · cited 1×
“Various classes of cytokines include: interleukins, chemokines, interferons, lymphokines, the tumor necrosis factor (TNF) family, and the transforming growth factor- (TGF-) family (Parkin and Cohen 2001; Platanias 2005; Sun and Fink 2007).”
BackgroundCalcineurin and hypertrophic heart disease: novel insights and remaining questions
Bueno, O. F., van Rooij, E., Molkentin, J. D., Doevendans, P. A., & Windt, L. J. D. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00493-x · Cited by 134 · cited 1×
“Subsequently, NFAT activates the transcription of pro-hypertrophic target genes (Bueno et al. 2002).”
BackgroundCardiomyocyte Apoptotic Cell Death in Arterial Hypertension: Mechanisms and Potential Management
Fortuño, M. A., Ravassa, S., Fortuño, A., Zalba, G., & Díez, J. (2001) · Hypertension · doi:10.1161/hy1201.099615 · Cited by 122 · cited 1×
“It is possible this stimulation of cardiomyocyte apoptosis contributes to the eventual decompensation in cardiac function which occurs when adaptive cardiac hypertrophy transitions to pathological cardiac hypertrophy (Fortuño et al. 2001).”
BackgroundLu, F. Y., Ellims, A., Beale, A. L., Taylor, A. J., Murphy, A. J., & Dart, A. M. (2017) · Europe PMC (PubMed Central) · Cited by 114
van Wamel, A. J. E. T., Ruwhof, C., van der Valk-Kokshoorn, L. J. M., Schriern, P. I., & van der Laarse, A. (2001) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007279700705 · Cited by 113 · cited 1×
“…Journal of Physiology and Pharmacology Draft 10 kinase, p38 mitogen-activated protein kinase (MAPK), and nuclear factor -light-chain-enhancer of activated B cells (Gray et al. 1998; Takimoto and Kass 2007; van Wamel et al. 2001; Weber et al. 2005; W. Zhang et al. 2003a).”
BackgroundDifferential cardiac hypertrophy and signaling pathways in pressure versus volume overload.
You, J., Wu, J., Zhang, Q., et al. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00212.2017 · Cited by 109 · cited 1×
“In a mouse model of pressure-overload-induced pathological cardiac hypertrophy, an increased rate of cardiomyocyte apoptosis was reported (You et al. 2017).”
BackgroundWeber, D. S., Rocic, P., Mellis, A. M., Laude, K., Lyle, A. N., Harrison, D. G., & Griendling, K. K. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00638.2004 · Cited by 104 · cited 1×
“…Journal of Physiology and Pharmacology Draft 10 kinase, p38 mitogen-activated protein kinase (MAPK), and nuclear factor -light-chain-enhancer of activated B cells (Gray et al. 1998; Takimoto and Kass 2007; van Wamel et al. 2001; Weber et al. 2005; W. Zhang et al. 2003a).”
BackgroundPathophysiology and Etiology of Heart Failure
Johnson, F. L. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.015 · Cited by 95 · cited 1×
“As well, an identifying characteristic of cardiomyopathy is an upregulation of cardiomyocyte apoptosis (Johnson 2014).”
BackgroundIDH2 deficiency promotes mitochondrial dysfunction and cardiac hypertrophy in mice
Ku, H. J., Ahn, Y., Lee, J. H., Park, K. M., & Park, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.12.018 · Cited by 88 · cited 1×
“As well, in the hearts of mice deficient in IDH2, caspase-3 and caspase-8, well-known markers of apoptosis, were significantly higher in comparison to the hearts of wild type (WT) mice (Ku et al. 2015).”
Endogenous Inflammatory Molecules Engage Toll-Like Receptors in Cardiovascular Disease
Ionita, M. G., Arslan, F., de Kleijn, D. P. V., & Pasterkamp, G. (2010) · Journal of Innate Immunity · doi:10.1159/000314270 · Cited by 83 · cited 1×
“…of cardiac remodeling and it has been suggested that this acute, pro-inflammatory Page 15 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Draft 16 stage is followed by an anti-inflammatory response to resolve the injury (Ionita et al. 2010).”
BackgroundFriehs, I., Margossian, R. E., Moran, A. M., Cao-Danh, H., Moses, M. A., & del Nido, P. J. (2005) · Basic Research in Cardiology · doi:10.1007/s00395-005-0581-0 · Cited by 80
Myometrial cytokines and their role in the onset of labour
Sivarajasingam, S. P., Imami, N., & Johnson, M. R. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0157 · Cited by 79 · cited 1×
“…both beneficial and deleterious effects on cellular function and are involved in the immune response, inflammation, sepsis, reproduction, trauma, cancer, and CVD (Padua et al. 1995; Parkin and Cohen 2001; Saini et al. 2005; Lee and Margolin 2011; Sivarajasingam et al. 2016; Guisasola et al. 2018).”
BackgroundSaini, H. K., Xu, Y., Zhang, M., Liu, P. P., Kirshenbaum, L. A., & Dhalla, N. S. (2005) · PubMed · Cited by 79
Self-citationMolecular mechanisms of cytokine receptor activation
Grötzinger, J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00316-6 · Cited by 78 · cited 1×
“These transmembrane receptors are divided into six types according to their structure (Arimont et al. 2017; Grötzinger 2002) and include type I and type II cytokine receptors, the immunoglobin superfamily of receptors, the TNF receptor family, chemokine receptors, and TGF- receptors.”
BackgroundZarain‐Herzberg, Á., Rupp, H., Elimban, V., & Dhalla, N. S. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.11.8836044 · Cited by 75
Self-citationLate INa increases diastolic SR-Ca2+-leak in atrial myocardium by activating PKA and CaMKII
Fischer, T. H., Herting, J., Mason, F. E., Hartmann, N., Watanabe, S., Nikolaev, V. O., Sprenger, J., Fan, P., Yao, L., Popov, A., et al. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv153 · Cited by 74 · cited 1×
“In addition, excessive cytosolic Ca2+ increases phosphorylation of RyR2, which stimulates the release of more Ca2+ from the SR through the RyR2, further contributing to cytosolic Ca2+-overload (Fischer et al. 2015; Popescu et al. 2016).”
BackgroundModesti, P. A., Vanni, S., Bertolozzi, I., Cecioni, I., Polidori, G., Paniccia, R., Bandinelli, B., Perna, A. M., Liguori, P., Boddi, M., et al. (2000) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2000.279.3.h976 · Cited by 73
Mitochondrial Reprogramming Induced by CaMKIIδ Mediates Hypertrophy Decompensation
Westenbrink, B. D., Ling, H., Divakaruni, A. S., Gray, C. B. B., Zambon, A. C., Dalton, N. D., Peterson, K. L., Gu, Y., Matkovich, S. J., Murphy, A. N., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.304682 · Cited by 72
Coronary arterial tree remodeling in right ventricular hypertrophy
Kassab, G. S., Imoto, K., White, F. C., Rider, C. A., Fung, Y. C., & Bloor, C. M. (1993) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1993.265.1.h366 · Cited by 71 · cited 1×
“During the adaptive stage of cardiac hypertrophy, enhanced coronary angiogenesis is observed (Kassab et al. 1993; Kassab et al. 2000; Yunlong 2007); however, there is ample evidence to indicate that capillary density within the heart is decreased at the later stages of pathological cardiac…”
BackgroundBenderdour, M., Charron, G., Comte, B., Ayoub, R., Beaudry, D., Foisy, S., deBlois, D., & Rosiers, C. D. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00378.2004 · Cited by 70 · cited 2×
“Within cardiomyocytes, IDH2 is abundantly expressed (Jo et al. 2001) and inhibition of IDH2 gene expression in cardiomyocytes induces apoptosis and pathological cardiac hypertrophy (Benderdour et al. 2004).”
BackgroundKumar, S., Wang, G., Liu, W., Ding, W., Dong, M., Zheng, N., Ye, H., & Liu, J. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.10845 · Cited by 69 · cited 1×
“Hypoxia-induced mitogenic factor (HIMF) has been shown to be upregulated in the heart and has a central role in the development of pathological cardiac hypertrophy (Kumar et al. 2018).”
BackgroundKarch, R., Neumann, F., Ullrich, R., Neumüller, J., Podesser, B. K., Neumann, M., & Schreiner, W. (2005) · Cardiovascular Pathology · doi:10.1016/j.carpath.2005.03.003 · Cited by 68
Effect of AT1 receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension
Diep, Q. N., Mabrouk, M. E., Yue, P., & Schiffrin, E. L. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00984.2001 · Cited by 68 · cited 1×
“The pro-hypertrophic signaling agonist Ang II, which stimulates pathological cardiac hypertrophy, has been reported to induce cardiomyocyte apoptosis (Diep et al. 2002).”
BackgroundFlanagan, M. F., Fujii, A. M., Colan, S. D., Flanagan, R. G., & Lock, J. E. (1991) · Circulation Research · doi:10.1161/01.res.68.5.1458 · Cited by 64 · cited 2×
“…et al. 2000; Yunlong 2007); however, there is ample evidence to indicate that capillary density within the heart is decreased at the later stages of pathological cardiac hypertrophy (Flanagan et al. 1991; Hamasaki et al. 2000; Hudlicka et al. 1992; Karch et al. 2005; Shimamatsu and Toshima 1987).”
BackgroundNie, J., Duan, Q., He, M., Li, X., Wang, B., Zhou, C., Wu, L., Zheng, W., Chen, C., Wang, D. W., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27791 · Cited by 64 · cited 11×
“Page 13 of 48 https://mc06.manuscriptcentral.com/cjpp-pubs Canadian Journal of Physiology and Pharmacology Draft 14 Calcineurin and CaMKII are Ca2+-dependent signaling proteins, which may be involved in pathological cardiac hypertrophy and adverse cardiac remodeling.”
BackgroundInfluentialHassan, A., & Kamal, M. M. (2013) · International Journal of Health Sciences · doi:10.12816/0006020 · Cited by 61 · cited 1×
“Furthermore, apoptosis of cardiomyocytes has been reported to be a key mechanism in the pathogenesis of heart failure (Hassan and Kamal 2013).”
BackgroundSDF-1 induces TNF-mediated apoptosis in cardiac myocytes
Jarrah, A. A., Schwarskopf, M., Wang, E. R., LaRocca, T., Dhume, A., Zhang, S., Hadri, L., Hajjar, R. J., Schecter, A. D., & Tarzami, S. T. (2017) · APOPTOSIS · doi:10.1007/s10495-017-1438-3 · Cited by 59
Loch, T., Vakhrusheva, O., Piotrowska, I., Ziolkowski, W., Ebelt, H., Braun, T., & Bober, E. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp092 · Cited by 57 · cited 1×
“This antioxidant defense system protects the heart from oxidative damage and the development of cardiac dysfunction (Shiomi et al. 2004; Nojiri et al. 2006; Loch et al. 2009; Huang et al. 2015).”
BackgroundCalcium sparks in human ventricular cardiomyocytes from patients with terminal heart failure
Lindner, M., Brandt, M. C., Sauer, H., Hescheler, J., Böhle, T., & Beuckelmann, D. J. (2002) · Cell Calcium · doi:10.1054/ceca.2002.0272 · Cited by 57 · cited 2×
“…of Physiology and Pharmacology Draft 13 Previous research has reported that Ca2+-handling abnormalities occur in the failing heart and contribute to the development of contractile dysfunction (Feldman et al. 1987; Gwathmey et al. 1987; Lindner et al. 2002; Yeh et al. 2008; Respress et al. 2014).”
BackgroundAn overview of cytokines and heat shock response in polytraumatized patients
Guisasola, M. C., Alonso, B., Bravo, B., Vaquero, J., & Chana, F. (2017) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0859-9 · Cited by 57
CRP Stimulates GDF15 Expression in Endothelial Cells through p53
Kim, Y., Hooten, N. N., & Evans, M. K. (2018) · Mediators of Inflammation · doi:10.1155/2018/8278039 · Cited by 52 · cited 1×
“Typically, GDF-15 is secreted at low levels; however, when cardiomyocytes are placed under stress, secretion of GDF-15 may be increased (Kim et al. 2018).”
BackgroundLi, X., Lan, Y., Wang, Y., Nie, M.-H., Lu, Y., & Zhao, E. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6318 · Cited by 48 · cited 1×
“Pathological cardiac hypertrophy is typically associated with cardiomyocyte apoptosis (Li et al. 2017), while cardiomyocyte apoptosis is not associated with physiological cardiac hypertrophy (Jin et al. 2000).”
BackgroundEskandari, V., Amirzargar, A., Mahmoudi, M., Rahnemoon, Z., Rahmani, F., sadati, S. S. S., Rahmati, Z., Gorzin, F., Hedayat, M., & Rezaei, N. (2017) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-017-1680-2 · Cited by 47
Ayça, B., Şahin, İ., Küçük, S. H., Akın, F., Kafadar, D., Avşar, M., Avcı, İ. İ., Güngör, B., Okuyan, E., & Dinçkal, M. H. (2015) · Clinical Cardiology · doi:10.1002/clc.22404 · Cited by 41 · cited 1×
“High level of TGF- in patients with hypertrophic cardiomyopathy was associated with elevated brain natriuretic peptide level, large left atrial size, thickened intraventricular septum, and increased frequency of adverse clinical events (Ayça et al. 2015).”
BackgroundEnhanced calcium transport by sarcoplasmic reticulum in mild cardiac hypertrophy
Limas, C., Spier, S. S., & Kahlon, J. (1980) · Journal of Molecular and Cellular Cardiology · doi:10.1016/0022-2828(80)90035-8 · Cited by 38 · cited 2×
“Both upregulation and downregulation of SR gene expression for SR proteins and Ca2+-transport activities have been observed without significant changes in myofibrillar ATPase activities (Arai 1996; Heyliger et al. 1985; de la Bastie et al. 1990; Kiss et al. 1995; Dhalla et al. 1987).”
Backgroundde Carvalho, B. M. R., Bassani, R. A., Franchini, K. G., & Bassani, J. W. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01345.2005 · Cited by 36 · cited 2×
“Following 1-week of cardiac pressure-overload, rat cardiomyocytes exhibited enhanced Ca2+ transients and SR Ca2+-uptake, indicating increased Ca2+-handling during adaptive cardiac hypertrophy (Carvalho et al. 2006).”
BackgroundInfluentialLong-term simulated microgravity causes cardiac RyR2 phosphorylation and arrhythmias in mice
Respress, J. L., Гершович, П. М., Wang, T., Reynolds, J. O., Skapura, D. G., Sutton, J. P., Miyake, C. Y., & Wehrens, X. H. T. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.138 · Cited by 36
Innate immunity and remodelling
Valen, G. (2010) · Heart Failure Reviews · doi:10.1007/s10741-010-9187-1 · Cited by 36
Xue, H., Fu, Z., Chen, Y., Xing, Y., Liu, J., Zhu, H., & Zhou, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046534 · Cited by 35 · cited 1×
“GDF-15 may therefore serve as a biomarker of CVD, including pathological cardiac hypertrophy (Xue et al. 2012).”
BackgroundDifferences in Concentric Cardiac Hypertrophy and Eccentric Hypertrophy
Muller, A. L., & Dhalla, N. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5203-4_8 · Cited by 31
Self-citationElevated local [Ca2+] and CaMKII promote spontaneous Ca2+release in ankyrin-B-deficient hearts
Popescu, I. R., Galice, S., Mohler, P. J., & Despa, S. I. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw093 · Cited by 31 · cited 1×
“In addition, excessive cytosolic Ca2+ increases phosphorylation of RyR2, which stimulates the release of more Ca2+ from the SR through the RyR2, further contributing to cytosolic Ca2+-overload (Fischer et al. 2015; Popescu et al. 2016).”
BackgroundKe, H., Yang, H., Francis, A. J., Collins, T. P., Surendran, H., Alvarez‐Laviada, A., Firth, J. M., & MacLeod, K. T. (2019) · The Journal of Physiology · doi:10.1113/jp277038 · Cited by 31
Takeo, S., Elmoselhi, A. B., Goel, R. K., Sentex, E., Wang, J., & Dhalla, N. S. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007120332587 · Cited by 27 · cited 1×
“…reduced SR Ca2+-uptake and Ca2+-release activity protein content and mRNA levels, decreased myofibrillar and myosin ATPase activities, as well as a shift in the composition of myosin isozymes (Rupp et al. 1992; Zarain-Herzberg et al. 1996; Dhalla et al. 1999; Liu et al. 1999; Takeo et al. 2000).”
BackgroundSelf-citationMeier, H., Bullinger, J., Marx, G., Deten, A., Horn, L., Raßler, B., Zimmer, H., & Briest, W. (2009) · Cellular Physiology and Biochemistry · doi:10.1159/000218180 · Cited by 25
Subcellular Remodeling and Heart Dysfunction in Cardiac Hypertrophy due to Pressure Overloada
Dhalla, N. S., Golfman, L. S., LIU, X., Sasaki, H., Vijayan Elimban, A., & Rupp, H. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09228.x · Cited by 24 · cited 2×
“…reduced SR Ca2+-uptake and Ca2+-release activity protein content and mRNA levels, decreased myofibrillar and myosin ATPase activities, as well as a shift in the composition of myosin isozymes (Rupp et al. 1992; Zarain-Herzberg et al. 1996; Dhalla et al. 1999; Liu et al. 1999; Takeo et al. 2000).”
BackgroundSelf-citationSu, H., Pistolozzi, M., Shi, X., Sun, X., & Tan, W. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx102 · Cited by 17 · cited 2×
“In a model of pathological cardiac hypertrophy induced by isoproterenol, changes in the balance between NO and ROS occurred (Su et al. 2017).”
BackgroundRegulation of Myocardial SERCA2a Expression in Ventricular Hypertrophy and Heart Failure
Muller, A., & Simonides, W. S. (2005) · Future Cardiology · doi:10.2217/14796678.1.4.543 · Cited by 13 · cited 1×
“SERCA2a impairment, a characteristic often associated with the transition to pathological cardiac hypertrophy, occurs in the later stages of adaptive cardiac hypertrophy (Muller and Simonides 2005).”
Background
Cited by
The role of cellular senescence in cardiac disease: basic biology and clinical relevance
Mehdizadeh, M., Aguilar, M., Thorin, E., Ferbeyre, G., & Nattel, S. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00624-2 · Cited by 304
Metadata
- Authors
- Oldfield, C. J., Duhamel, T. A., & Dhalla, N. S.
- Venue
- Canadian Journal of Physiology and Pharmacology
- Publisher
- Canadian Science Publishing
- Published
- 2020-02
- Volume
- 98
- Issue
- 2
- Pages
- 74-84
- ISSN
- 0008-4212 (ISSN-L)
- 1205-7541
- OpenAlex
- W2994875986
- Cited by
- 204
- References
- 152
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.